SCHEMBL2346509

SCHEMBL2346509

O=S(=O)(Nc1ccc(N2CCNCC2)nc1)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.66
ALOX12 P18054 1/20 0.59
MLNR O43193 2/20 0.57
KMT2A Q03164 3/20 0.57
GAA P10253 2/20 0.57
MEN1 O00255 2/20 0.57
KDM4E B2RXH2 2/20 0.54
HTR1A P08908 1/20 0.51
HTR1D P28221 1/20 0.51
HTR1B P28222 1/20 0.51
HTR2A P28223 1/20 0.51
HSP90AA1 P07900 1/20 0.50
HSP90AB1 P08238 1/20 0.50
RIPK2 O43353 1/20 0.48
ACVR1 Q04771 1/20 0.48
NOD2 Q9HC29 1/20 0.48
LMNA P02545 2/20 0.48
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
PLD1 Q13393 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18553804 0.87 HTR6 (0.59) HTR6ALOX12MLNRKMT2AGAA
SCHEMBL28145250 0.85 KMT2A (0.78) MLNRKMT2AGAAMEN1KDM4E
SCHEMBL4686763 0.84 KMT2A (0.60) HTR6ALOX12MLNRKMT2AGAA
SCHEMBL7485675 0.81 GAA (0.64) ALOX12MLNRKMT2AGAAMEN1
SCHEMBL30307834 0.81 GAA (0.64) ALOX12MLNRKMT2AGAAMEN1
SCHEMBL18553766 0.80 HTR6 (1.00) HTR6ALOX12KMT2AMEN1KDM4E
SCHEMBL7485653 0.78 ALOX12 (0.50) ALOX12MLNRKMT2AGAAMEN1
SCHEMBL7488327 0.77 GAA (0.59) ALOX12MLNRKMT2AGAAMEN1
SCHEMBL38663688 0.76 HRH4 (0.55) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL16646179 0.76 ALOX12 (1.00) ALOX12GAALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150175570-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2015-06-25 US claimed
CN-101687802-B Benzenesulfonamide compounds suitable for the treatment of disorders which respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO KG 2014-02-26 CN claimed
EP-2203426-B9 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2013-02-13 EP claimed
US-20110319421-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO., KG (DE) 2011-12-29 US claimed
EP-2203426-B1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-08-31 EP claimed
US-20100210664-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-08-19 US claimed
EP-2203426-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2010-07-07 EP claimed
CN-101687802-A Is suitable for treating dopamine D3Benzenesulfonamide compounds which modulate receptor-responsive disorders ABBOTT GMBH & CO KG 2010-03-31 CN claimed
WO-2009056600-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-05-07 WO claimed
US-20150175570-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2015-06-25 US disclosed
CN-101687802-B Benzenesulfonamide compounds suitable for the treatment of disorders which respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO KG 2014-02-26 CN disclosed
EP-2203426-B9 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2013-02-13 EP disclosed
US-20110319421-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO., KG (DE) 2011-12-29 US disclosed
EP-2203426-B1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-08-31 EP disclosed
US-20100210664-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-08-19 US disclosed
EP-2203426-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2010-07-07 EP disclosed
CN-101687802-A Is suitable for treating dopamine D3Benzenesulfonamide compounds which modulate receptor-responsive disorders ABBOTT GMBH & CO KG 2010-03-31 CN disclosed
WO-2009056600-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175570-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR DRD3, SLC6A3, DRD2 HTR6 130/4885ALOX12 1160/4885MLNR 489/4885
US-20100210664-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR DRD3, SLC6A3, DRD2 HTR6 130/4885ALOX12 1160/4885MLNR 489/4885
US-20110319421-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR DRD3, SLC6A3, DRD2 HTR6 130/4885ALOX12 1160/4885MLNR 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.